Corcept Therapeutics (CORT) Return on Sales (2016 - 2025)
Historic Return on Sales for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 0.09%.
- Corcept Therapeutics' Return on Sales fell 1600.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.14%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.21% for FY2024, which is 100.0% down from last year.
- According to the latest figures from Q3 2025, Corcept Therapeutics' Return on Sales is 0.09%, which was down 1600.0% from 0.18% recorded in Q2 2025.
- Corcept Therapeutics' Return on Sales' 5-year high stood at 0.34% during Q3 2022, with a 5-year trough of 0.09% in Q3 2025.
- Over the past 5 years, Corcept Therapeutics' median Return on Sales value was 0.23% (recorded in 2023), while the average stood at 0.23%.
- In the last 5 years, Corcept Therapeutics' Return on Sales surged by 700bps in 2021 and then plummeted by -1600bps in 2022.
- Quarter analysis of 5 years shows Corcept Therapeutics' Return on Sales stood at 0.32% in 2021, then tumbled by -50bps to 0.16% in 2022, then surged by 44bps to 0.23% in 2023, then fell by -27bps to 0.17% in 2024, then crashed by -44bps to 0.09% in 2025.
- Its Return on Sales stands at 0.09% for Q3 2025, versus 0.18% for Q2 2025 and 0.13% for Q1 2025.